- Report
- May 2026
- 350 Pages
Global
From €3580EUR$3,995USD£3,066GBP
- Report
- March 2026
- 960 Pages
Global
From €2957EUR$3,300USD£2,533GBP
- Report
- June 2026
- 200 Pages
Global
From €2679EUR$2,990USD£2,295GBP
- Report
- July 2026
- 188 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- January 2026
- 190 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- August 2026
- 224 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 377 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 104 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 381 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 392 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP

Cancer Monoclonal Antibodies (mAbs) are a type of oncology drug used to treat cancer. They are a type of biologic therapy, which means they are made from living cells. mAbs are designed to target specific proteins on cancer cells, which can help to slow or stop the growth of the cancer. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. mAbs can be used to treat a variety of cancers, including breast, lung, and colorectal cancer.
The Cancer Monoclonal Antibodies market is a rapidly growing segment of the oncology drugs market. mAbs are becoming increasingly popular due to their ability to target specific proteins on cancer cells, which can help to reduce side effects and improve outcomes. Additionally, mAbs are often more cost-effective than other treatments, making them attractive to healthcare providers.
Some of the major companies in the Cancer Monoclonal Antibodies market include Roche, Merck, Bristol-Myers Squibb, Amgen, and Novartis. Show Less Read more